select a format

Single User License
USD 250 INR 16030
Site License
USD 500 INR 32060
Corporate User License
USD 750 INR 48090

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Par Pharmaceutical Holdings Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Par Pharmaceutical Holdings Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH32098D
  • |
  • Pages: 50
  • |
  • November 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Par Pharmaceutical Holdings Inc (Par Pharmaceutical Holdings) carries out the research, development, manufacture, commercialization and distribution of generic and branded drugs in the US. Its generic products include oral solids, oral suspensions, gels, nasal sprays, and injectables. It also markets authorized in-licensed generic drugs. Some of its branded products include Nascobal, a nasal spray; and Megace ES, which is indicated for the treatment of anorexia, cachexia or for weight loss in patients diagnosed with AIDS. The company also offers branded and generic aseptic injectables. It manufactures all the products in its manufacturing facilities in India and the US. It markets generic products through wholesalers, drug store chains, super market chains, mass merchandisers, distributors, and government and mail order accounts. Par Pharmaceutical Holdings is headquartered in Woodcliff Lake, New Jersey, the US.

Par Pharmaceutical Holdings Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9

Par Pharmaceutical Holdings Inc, Medical Devices Deals, 2010 to YTD 2016 11

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 14

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 15

Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 17

Private Equity 19

TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For US$1.9 Billion 19

Partnerships 22

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 22

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 23

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma 24

Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 25

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Accolate 26

Licensing Agreements 27

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 27

Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 28

Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 29

Jazz Pharma Enters Into Sub-Licensing Agreement With Anchen 30

Par Pharma Enters Licensing Agreement With Glenmark Generics 31

Debt Offering 33

Par Pharma Completes Private Placement Of Notes Due 2020 For US$490 Million 33

Asset Transactions 34

Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 34

Acquisition 36

Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 36

Par Pharma Acquires Innoteq for USD27 Million 39

Par Pharma Reportedly Acquires Ethics Bio Lab 40

Par Pharma Acquires JHP Group for USD488 Million 41

Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For US$24.9 Million 42

Par Pharma Acquires Anchen Pharma For US$410 Million 44

Par Pharmaceutical Holdings Inc-Key Competitors 46

Key Employees 47

Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9

Par Pharmaceutical Holdings Inc, Medical Devices Deals, 2010 to YTD 2016 11

List of Tables

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2014 1

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8

Par Pharmaceutical Holdings Inc, Deals By Therapy Area, 2010 to YTD 2016 9

Par Pharmaceutical Holdings Inc, Medical Devices Deals, 2010 to YTD 2016 11

Par Pharmaceutical Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12

Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 14

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 15

Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 17

TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For US$1.9 Billion 19

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 22

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 23

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma 24

Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 25

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Accolate 26

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 27

Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 28

Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 29

Jazz Pharma Enters Into Sub-Licensing Agreement With Anchen 30

Par Pharma Enters Licensing Agreement With Glenmark Generics 31

Par Pharma Completes Private Placement Of Notes Due 2020 For US$490 Million 33

Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 34

Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 36

Par Pharma Acquires Innoteq for USD27 Million 39

Par Pharma Reportedly Acquires Ethics Bio Lab 40

Par Pharma Acquires JHP Group for USD488 Million 41

Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For US$24.9 Million 42

Par Pharma Acquires Anchen Pharma For US$410 Million 44

Par Pharmaceutical Holdings Inc, Key Competitors 46

Par Pharmaceutical Holdings Inc, Key Employees 47

Par Pharmaceutical Holdings Inc, Subsidiaries 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Par Pharmaceutical Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com